DK1487493T3 - Konjugater af cytotoksiske midler og biologisk aktive peptider - Google Patents
Konjugater af cytotoksiske midler og biologisk aktive peptiderInfo
- Publication number
- DK1487493T3 DK1487493T3 DK03716299.7T DK03716299T DK1487493T3 DK 1487493 T3 DK1487493 T3 DK 1487493T3 DK 03716299 T DK03716299 T DK 03716299T DK 1487493 T3 DK1487493 T3 DK 1487493T3
- Authority
- DK
- Denmark
- Prior art keywords
- biologically active
- conjugates
- cytotoxic agents
- active peptides
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36083102P | 2002-03-01 | 2002-03-01 | |
| PCT/US2003/006657 WO2003074551A2 (en) | 2002-03-01 | 2003-03-03 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1487493T3 true DK1487493T3 (da) | 2010-05-25 |
Family
ID=27789031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03716299.7T DK1487493T3 (da) | 2002-03-01 | 2003-03-03 | Konjugater af cytotoksiske midler og biologisk aktive peptider |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7771727B2 (da) |
| EP (1) | EP1487493B1 (da) |
| JP (1) | JP4477881B2 (da) |
| KR (1) | KR101003622B1 (da) |
| CN (2) | CN102133407A (da) |
| AT (1) | ATE455561T1 (da) |
| AU (1) | AU2003220011B2 (da) |
| BR (1) | BR0308090A (da) |
| CA (1) | CA2476182A1 (da) |
| CO (1) | CO5611160A2 (da) |
| DE (1) | DE60331049D1 (da) |
| DK (1) | DK1487493T3 (da) |
| ES (1) | ES2339934T3 (da) |
| IL (1) | IL163573A0 (da) |
| IS (1) | IS7431A (da) |
| MX (1) | MXPA04008419A (da) |
| NO (1) | NO20044039L (da) |
| NZ (1) | NZ534719A (da) |
| PL (1) | PL373567A1 (da) |
| WO (1) | WO2003074551A2 (da) |
| ZA (1) | ZA200406614B (da) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
| ATE483476T1 (de) * | 2003-03-20 | 2010-10-15 | Nippon Kayaku Kk | Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer |
| WO2004083432A1 (en) | 2003-03-21 | 2004-09-30 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| KR20070108953A (ko) * | 2003-04-22 | 2007-11-13 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | 펩타이드 벡터 |
| US20060281897A1 (en) * | 2003-08-22 | 2006-12-14 | Andre Trouet | Potentialization of the activation of high molecular weight prodrugs |
| CA2542834C (en) | 2003-10-21 | 2012-04-24 | Igf Oncology, Llc | Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents |
| US9011880B2 (en) | 2003-10-21 | 2015-04-21 | Igf Oncology, Llc | Compounds and methods for treating cancer |
| CA2581125C (en) | 2004-09-22 | 2013-04-23 | Nippon Kayaku Kabushiki Kaisha | Modified poly(ethylene oxide-amino acid) copolymer, micelle preparation, and anticancer agent containing the same |
| WO2006047214A2 (en) | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
| KR100897915B1 (ko) * | 2004-11-03 | 2009-05-18 | 포휴먼텍(주) | 경피전달을 위한 약제 조성물 |
| US7598375B2 (en) | 2005-08-09 | 2009-10-06 | Millenium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| US8940332B2 (en) * | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| EP2046954A2 (en) | 2006-07-31 | 2009-04-15 | Curevac GmbH | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
| PT2049664E (pt) | 2006-08-11 | 2012-01-03 | Prosensa Technologies Bv | Oligonucleotídeos de cadeia simples complementares dos elementos repetitivos para tratar perturbações genéticas associadas à instabilidade das repetições do adn |
| JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
| CA2693742A1 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| AU2008273096B2 (en) | 2007-07-12 | 2013-05-02 | Academisch Ziekenhuis Leiden | Molecules for targeting compounds to various selected organs or tissues |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| JP5349318B2 (ja) * | 2007-09-28 | 2013-11-20 | 日本化薬株式会社 | ステロイド類の高分子結合体 |
| DK2203173T3 (da) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Midler og fremgangsmåder til modvirkning af muskellidelser |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| EP2548960B1 (en) | 2008-01-31 | 2018-01-31 | CureVac AG | Nucleic acids comprising formula (nugixmgnv)a and derivatives thereof as an immunostimulating agents/adjuvant |
| WO2009099326A1 (en) | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2258397B1 (en) * | 2008-03-18 | 2017-10-11 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of physiologically active substance |
| EP2284209B1 (en) | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN101439182B (zh) * | 2008-12-18 | 2012-02-01 | 北京大学 | 一种生长抑素受体介导的肿瘤靶向药物组合物 |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| EP2421971B1 (en) | 2009-04-24 | 2016-07-06 | BioMarin Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
| EP2431403B1 (en) | 2009-05-15 | 2016-09-28 | Nipponkayaku Kabushikikaisha | Polymer conjugate of bioactive substance having hydroxy group |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| AU2010335039B2 (en) | 2009-12-24 | 2015-03-26 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Molecule for treating an inflammatory disorder |
| EP2955230A1 (en) | 2010-07-30 | 2015-12-16 | CureVac AG | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| TW201304805A (zh) | 2010-11-17 | 2013-02-01 | Nippon Kayaku Kk | 新穎之胞核苷系代謝拮抗劑之高分子衍生物 |
| US9540438B2 (en) | 2011-01-14 | 2017-01-10 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof |
| CA2862798C (en) | 2011-02-17 | 2021-04-06 | The Administrators Of The Tulane Educational Fund | Multicomponent compositions and their uses |
| JP5711378B2 (ja) | 2011-09-11 | 2015-04-30 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
| CN104203289B (zh) | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2844300B1 (en) * | 2012-05-01 | 2018-10-17 | Genentech, Inc. | Anti-pmel17 antibodies and immunoconjugates |
| CN107982545B (zh) | 2012-05-15 | 2021-04-09 | 联宁（苏州）生物制药有限公司 | 药物偶联物，偶联方法，及其用途 |
| MA38496B2 (fr) * | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
| SG10201801431TA (en) | 2013-08-21 | 2018-04-27 | Curevac Ag | Respiratory syncytial virus (rsv) vaccine |
| AU2015204540B2 (en) | 2014-01-12 | 2020-03-19 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| CN105198966B (zh) * | 2014-06-26 | 2019-06-21 | 中国人民解放军军事医学科学院毒物药物研究所 | GnRH类似物-细胞毒分子缀合物、其制备方法及用途 |
| CA2953371C (en) | 2014-06-30 | 2021-08-24 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| CA2955569C (en) * | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| CN113201049B (zh) * | 2015-08-05 | 2022-10-04 | 陕西麦科奥特科技有限公司 | 有抗凝血和抗血小板活性的多靶点化合物及制法和用途 |
| CN106466485B (zh) * | 2015-08-11 | 2021-05-04 | 同宜医药（苏州）有限公司 | 一种具有细胞内吞介导功能的靶向配体-药物偶联体 |
| EP3368546A4 (en) | 2015-10-28 | 2019-06-26 | Tarveda Therapeutics, Inc. | SSTR TARGETED CONJUGATES, AND ITS PARTICLES AND FORMULATIONS |
| WO2017165607A1 (en) | 2016-03-24 | 2017-09-28 | The Administrators Of The Tulane Educational Fund | Conjugates of tacrolimus, their compositions, and their uses |
| US11208632B2 (en) | 2016-04-26 | 2021-12-28 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| CN106492226A (zh) * | 2016-10-13 | 2017-03-15 | 武汉大学苏州研究院 | 肿瘤靶向性多肽—蒽环类衍生物 |
| CA3059593A1 (en) | 2017-05-21 | 2018-11-29 | Igf Oncology, Llc | An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| JP7267998B2 (ja) * | 2017-08-19 | 2023-05-02 | オハイオ・ステイト・イノベーション・ファウンデーション | 新規ペプチド系癌造影剤 |
| CN110357947B (zh) * | 2019-03-08 | 2023-05-26 | 南京恒远科技开发有限公司 | 一种combretastatin A4衍生物 |
| US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| EP3996749A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| RU2727924C1 (ru) * | 2019-08-20 | 2020-07-27 | Открытое акционерное общество "Всероссийский научный центр молекулярной диагностики и лечения" (ОАО "ВНЦМДЛ") | Высокоэффективный способ получения лекарственной формы адресного действия для терапии злокачественных новообразований |
| EP4351653A1 (en) * | 2021-06-09 | 2024-04-17 | Radionetics Oncology, Inc. | Non-peptide targeted therapeutics and uses thereof |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663306A (en) | 1984-08-09 | 1997-09-02 | Chiron Corporation | Method of conjugating an activated ester to an amine-containing biological material |
| US4904642A (en) | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
| US5073541A (en) | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
| US5753627A (en) | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5633263A (en) | 1989-04-26 | 1997-05-27 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
| EP0436005B1 (en) | 1989-07-20 | 1995-03-29 | Sandoz Ltd. | Labeled polypeptide derivatives |
| US5443815A (en) | 1991-11-27 | 1995-08-22 | Diatech, Inc. | Technetium-99m labeled peptides for imaging |
| US5411943A (en) | 1992-02-25 | 1995-05-02 | Biomeasure, Inc. | Hepatoma treatment with somatostatin analogs |
| US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
| US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
| US5597894A (en) | 1995-06-05 | 1997-01-28 | The Louisiana State University Medical Center Foundation | Multi-tyrosinated somatostatin analogs |
| US6051554A (en) | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US5770687A (en) | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
| US5708135A (en) | 1995-09-29 | 1998-01-13 | Biomeasure Incorporated | Cyclic peptide analogs of somatostatin |
| US5750499A (en) | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| US5843903A (en) | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| US6156725A (en) | 1996-08-16 | 2000-12-05 | National Institute Of Immunology | Drug for the treatment of cancer |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US5919934A (en) * | 1997-02-19 | 1999-07-06 | The George Washington University | Compounds, compositions, and methods for cancer imaging and therapy |
| US6200546B1 (en) | 1997-04-22 | 2001-03-13 | The Curators Of The University Of Missouri | Gastrin receptor-avid peptide conjugates |
| US6465613B1 (en) | 1998-11-19 | 2002-10-15 | Tulane University | Hydrophilic somatostatin analogs |
| AU1607501A (en) | 1999-11-15 | 2001-05-30 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| AU4267700A (en) | 2000-01-13 | 2001-07-19 | Academia Sinica | Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells |
| US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| KR20040047846A (ko) | 2001-09-21 | 2004-06-05 | 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 | 진단 또는 치료용 소마토스타틴 또는 봄베신 유사체콘쥬게이트 및 이들의 용도 |
-
2003
- 2003-03-03 PL PL03373567A patent/PL373567A1/xx not_active Application Discontinuation
- 2003-03-03 EP EP03716299A patent/EP1487493B1/en not_active Expired - Lifetime
- 2003-03-03 CN CN2010106215969A patent/CN102133407A/zh active Pending
- 2003-03-03 JP JP2003573017A patent/JP4477881B2/ja not_active Expired - Lifetime
- 2003-03-03 DE DE60331049T patent/DE60331049D1/de not_active Expired - Lifetime
- 2003-03-03 DK DK03716299.7T patent/DK1487493T3/da active
- 2003-03-03 AU AU2003220011A patent/AU2003220011B2/en not_active Ceased
- 2003-03-03 CN CNA038099276A patent/CN1649625A/zh active Pending
- 2003-03-03 AT AT03716299T patent/ATE455561T1/de active
- 2003-03-03 IL IL16357303A patent/IL163573A0/xx unknown
- 2003-03-03 ES ES03716299T patent/ES2339934T3/es not_active Expired - Lifetime
- 2003-03-03 MX MXPA04008419A patent/MXPA04008419A/es active IP Right Grant
- 2003-03-03 BR BRPI0308090-0A patent/BR0308090A/pt not_active IP Right Cessation
- 2003-03-03 KR KR1020047013597A patent/KR101003622B1/ko not_active IP Right Cessation
- 2003-03-03 CA CA002476182A patent/CA2476182A1/en not_active Abandoned
- 2003-03-03 US US10/506,223 patent/US7771727B2/en not_active Expired - Fee Related
- 2003-03-03 WO PCT/US2003/006657 patent/WO2003074551A2/en active Application Filing
- 2003-03-03 NZ NZ534719A patent/NZ534719A/en not_active IP Right Cessation
-
2004
- 2004-08-19 ZA ZA200406614A patent/ZA200406614B/en unknown
- 2004-08-31 IS IS7431A patent/IS7431A/is unknown
- 2004-09-24 NO NO20044039A patent/NO20044039L/no not_active Application Discontinuation
- 2004-09-29 CO CO04097209A patent/CO5611160A2/es not_active Application Discontinuation
-
2009
- 2009-08-25 US US12/547,096 patent/US20090324620A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003220011A1 (en) | 2003-09-16 |
| EP1487493A2 (en) | 2004-12-22 |
| ES2339934T3 (es) | 2010-05-27 |
| PL373567A1 (en) | 2005-09-05 |
| WO2003074551A3 (en) | 2004-03-25 |
| IS7431A (is) | 2004-08-31 |
| EP1487493B1 (en) | 2010-01-20 |
| JP2006510571A (ja) | 2006-03-30 |
| KR101003622B1 (ko) | 2010-12-24 |
| WO2003074551A2 (en) | 2003-09-12 |
| MXPA04008419A (es) | 2004-11-26 |
| CN102133407A (zh) | 2011-07-27 |
| CO5611160A2 (es) | 2006-02-28 |
| ZA200406614B (en) | 2006-06-28 |
| CA2476182A1 (en) | 2003-09-12 |
| IL163573A0 (en) | 2005-12-18 |
| CN1649625A (zh) | 2005-08-03 |
| BR0308090A (pt) | 2006-04-11 |
| AU2003220011B2 (en) | 2008-05-29 |
| EP1487493A4 (en) | 2006-08-30 |
| US7771727B2 (en) | 2010-08-10 |
| US20060009622A1 (en) | 2006-01-12 |
| DE60331049D1 (de) | 2010-03-11 |
| JP4477881B2 (ja) | 2010-06-09 |
| KR20040088568A (ko) | 2004-10-16 |
| NO20044039L (no) | 2004-09-29 |
| NZ534719A (en) | 2008-02-29 |
| US20090324620A1 (en) | 2009-12-31 |
| ATE455561T1 (de) | 2010-02-15 |
| WO2003074551A8 (en) | 2005-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1487493T3 (da) | Konjugater af cytotoksiske midler og biologisk aktive peptider | |
| CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
| YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
| CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
| DE60031248D1 (de) | Elektroaktive pore | |
| BR0107691A (pt) | Sapogeninas substituìdas e seu uso | |
| DE60239707D1 (de) | Antimikrobielle kationische peptide und diese enthaltende formulierungen | |
| BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
| DE60010098D1 (de) | 28-epirapaloge | |
| TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
| ATE305932T1 (de) | Rapanycin29-enole | |
| CY1109119T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη | |
| CY1108109T1 (el) | Χρηση cci-779 ως αντινεοπλασματικου παραγοντα | |
| CY1108610T1 (el) | Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες | |
| DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| SE9904377D0 (sv) | Pharmaceutical combinations | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| ATE419268T1 (de) | Haemasterlin analoge | |
| NO20031860L (no) | Kahalalid F | |
| NO20033123L (no) | Terapeutisk hinne dannende sammensetning og behandlingsplan derav | |
| CY1113083T1 (el) | Ασβεστιολυτικες ενωσεις | |
| DK1713438T3 (da) | Medicinsk sæbe | |
| BRPI0417265A (pt) | composição farmacêutica compreendendo um princìpio ativo e sulfobetaìna | |
| DK1274450T3 (da) | Medicinsk anvendelse af agonister og antagonister af IL-174 | |
| NO20005548D0 (no) | Mykobakterieinhibitorer |